Enzymatica AB: Enzymatica enters into partnership agreement with STADA Arzneimittel AG
13 February 2017 - 6:30PM
Press Release
Lund February 13, 2017
Enzymatica enters into
partnership agreement with STADA Arzneimittel AG
The agreement grants STADA
exclusive rights to sell, market and distribute Enzymatica's common
cold product ColdZyme® in Germany. Stada is a global pharmaceutical
company, headquartered in Germany, with a strong presence in Europe
and leading positions in the cough and cold category in Germany,
UK, and Russia.
"We are very
pleased to have signed the agreement with STADA as our marketing,
sales, and distribution partner for Germany, particularly since
Germany is the single largest market for over-the-counter products
in Europe. This agreement confirms the commercial potential for
ColdZyme outside of Scandinavia, and endorses the interest in
Enzymatica's technology platform", says Fredrik Lindberg, CEO
of Enzymatica.
"We are very excited about our agreement with
Enzymatica to help maximize the ColdZyme opportunity in
Germany. ColdZyme's unique
product offering is different to traditional cold therapies and is
a perfect fit to our existing portfolio as well as to our strategy
of growing our branded business on the back of
launching innovative, new products", says Wolfram Gollin, Head
of Marketing STADA GmbH.
The company's first product, ColdZyme, is a unique
mouth spray for use against the common cold.
In Europe, ColdZyme is directly marketed and sold by Enzymatica in
Sweden, Norway and Denmark and sold through marketing and sales
partners in Spain, Finland, Iceland and Greece. In the UK, the
ColdZyme business is handled by a sales agent.
For more information, please
contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com
This information is information
that Enzymatica AB (publ) is obliged to make public pursuant to the
EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out
above, at 0830 CET on February 13,
2017.
Enzymatica
Enzymatica is a life science company who develops and sells medical
device products against infectious-related diseases. Over a short
period the company has developed a unique oral spray for colds,
ColdZyme®, and launched it on eight markets. The product has become
one of the leading articles for colds in Swedish pharmacies.
Enzymatica's strategy is to continue growing by strengthening its
position in existing markets and to expand to more geographical
markets through well-established partners. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North.
For more information, please visit www.enzymatica.com.
Enzymaticas Certified Adviser is Erik Penser
Bank.
Stada Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed
globally leading generics producer with a traditionally strong
presence in Europe and especially Germany. STADA is
internationally-oriented and the Top 5 markets are Germany, Russia,
UK, Italy and Spain. STADA generated Group sales of € 2.115,1
million in 2015 and had 10,532 employees worldwide. Stada has its
headquarters in Bad Vilbel, Germany.
For more information visit www.stada.com
Enzymatica Press Release
Stada
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024